ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1614159
Bibliometric analysis and initial animal efficacy evaluation of top ten scoring drugs to enhance oral rehydration therapy in early post-burn shock
Provisionally accepted- 1Graduate School, Chinese PLA General Hospital, Beijing, China
- 2Senior Department of Burns & Plastic Surgery, Institute of Burn in the Fourth Medical Centre, Chinese PLA General Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background/Objectives: Burns can cause severe physiological disturbances. Oral rehydration therapy (ORT) is an alternative to intravenous fluids. However, the World Health Organizationrecommended oral rehydration solution (WHO-ORS) lacks specific components to address the critical physiological changes in patients with burns. This study aimed to identify and evaluate several drugs that enhance the ORT efficacy in burn shock management. Methods: A systematic search of PubMed, Web of Science, and Scopus (2000.01.01-2024.06.30) yielded 1,500 relevant studies, from which 270 were selected for bibliometric analysis. Drug candidates (≥3 mentions) were prioritized via the Bibliometric Evidence Score (BES) integrating publication frequency, journal impact factor (5-year average), impact score, and Q1 journal distribution. Subsequently, the translational potential of these candidates was assessed using an Integrated Translational Score incorporating weighted dimensions: Mechanistic Clinical Alignment Score (weight=0.45), Emergency Deployment Feasibility (weight=0.20), and BES (weight=0.35). The top 10 drugs by the BES were selected for experimental validation, which were tested in a rat model with 50% total body surface area full-thickness burns (n=286, 22/group), comparing sham controls, untreated controls, WHO-ORS, and drug-adjuvanted ORS groups. Primary outcomes included 48h survival rate and blood lactate (Lac), hematocrit (HCT), malondialdehyde (MDA), and interleukin-6 (IL-6) levels. Results: Teprenone or vitamin C in combination with the WHO-ORS significantly improved survival outcomes following severe burns. They reduced blood lactate, HCT, MDA, and IL-6 levels. Glutamine and ethyl pyruvate showed beneficial effects but did not significantly improve survival. Hypertonic Saline and Dobutamine failed to demonstrate efficacy. Conclusions: This study demonstrated that adding teprenone or vitamin C to the WHO-recommended ORS can enhance the therapeutic efficacy of ORT in managing burn shock. These findings provide a scientific basis for further clinical trials and development of optimized ORS for patients with burns.
Keywords: burn, Shock, oral rehydration therapy, World Health Organization-recommended oral rehydration solution, drug screening, bibliometric analysis, animal experiment, clinical application
Received: 18 Apr 2025; Accepted: 07 Aug 2025.
Copyright: © 2025 Liu, Wu, Qu, Zhou, Liu, Su, Hu, Zheng, Han, Chi and Chai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jia Ke Chai, Senior Department of Burns & Plastic Surgery, Institute of Burn in the Fourth Medical Centre, Chinese PLA General Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.